This article refers to:
Correction to: Certolizumab pegol for the treatment of psoriatic arthritis
Hansen RB, Kavanaugh A. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Rev Clin Immunology 2015:11(3):307-18.
On page 7, under Regulatory Affairs, it reads:
In 2009, the European Commission approved CZP for the treatment of active PsA in adults when the response to previous DMARD therapy has been inadequate. CZP can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriate [45]. The FDA approved CZP for the treatment of adult patients with active PsA in 2013.
However the EMA issued a positive opinion on CZP for the treatment of active PsA in 2013 (not 2009).